


# PRODUCT INFORMATION



## Farampator

Item No. 21510

**CAS Registry No.:** 211735-76-1  
**Formal Name:** 2,1,3-benzoxadiazol-5-yl-1-piperidinyl-methanone  
**Synonym:** CX-691  
**MF:** C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>  
**FW:** 231.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 295 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Farampator is supplied as a crystalline solid. A stock solution may be made by dissolving the farampator in the solvent of choice, which should be purged with an inert gas. Farampator is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of farampator in these solvents is approximately 20 and 30 mg/ml, respectively.

Farampator is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, farampator should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Farampator has a solubility of approximately 0.025 mg/ml in a 1:40 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Farampator is a positive allosteric modulator of AMPA receptors that has an EC<sub>50</sub> value greater than 32 μM for evoking glutamate currents in isolated pyramidal neurons.<sup>1</sup> In rats, it enhances novel object recognition memory (0.1 mg/kg, p.o.) and attentional set-shifting (0.3 mg/kg, p.o.) and reverses a scopolamine-induced deficit in cued fear conditioning (0.1 mg/kg, p.o.).<sup>2</sup>

### References

1. Menniti, F.S., Lindsley, C.W., Conn, P.J., *et al.* Allosteric modulators for the treatment of schizophrenia: Targeting glutamatergic networks. *Curr. Top. Med. Chem.* **13**(1), 26-54 (2013).
2. Woolley, M.L., Waters, K.A., Garlton, J.E., *et al.* Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. *Psychopharmacol.(Berl)*. **202**(1-3), 343-354 (2009).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/14/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM